Compared to placebo, the use of CGRP monoclonal antibody contributed to greater reductions in the number of monthly migraine days from baseline (WMD = −2.13, 95% CI: −2.55 to −1.71, p < 0.001), with low heterogeneity (I2 = 0%). The gene discussed is CALCA; the disease is migraine disorder.